- The REACT study imaged 16,808 adults aged 18 to 70 with no known heart disease and found atherosclerotic plaque in 57.1% of them. At 18 to 29 it was 8.7% of men and 6.7% of women, about 1 in 13; by 60 to 70 it was about 9 in 10 (New England Journal of Medicine, August 2026)
- Men got there first. By 50, half of men had silent plaque against 30% of women, whose steepest rise came later, around the age of menopause
- The standard risk score barely noticed. SCORE2, Europe's equivalent of the US risk calculator, classed only a small minority of people with plaque as high risk, and almost none of the young ones
- Two blood tests look at what the lipid panel doesn't. ApoB counts the particles that actually enter the artery wall; Lp(a) is a genetic particle about 1 in 5 people carry in excess. Both cost under $70 and the 2026 ACC/AHA guideline now covers both
- Finding plaque isn't the same as preventing a heart attack. REACT shows how early the disease starts, not that screening everyone saves lives. The practical move is to know your apoB and Lp(a), then talk to your doctor about what they mean for you
"Apparently healthy" is doing a lot of work in most heart studies. It means no chest pain, no diagnosis, no stents, a normal-looking cholesterol test. A study published this summer took 16,808 people who fit that description, aged 18 to 70, and looked directly inside their arteries. More than half had plaque.
That number travelled fast, and it deserves to. But a prevalence study tells you where the disease is, not what to do about it. This article covers what REACT actually found, why the usual risk score missed most of it, and the two blood tests, apolipoprotein B and lipoprotein(a), that measure the particles behind the plaque: what they are, what the numbers mean, how to get them and what they cost.
Plaque Decades Before Symptoms
Evidence: Strong for prevalence — large, balanced imaging cohort; cross-sectionalREACT was run jointly from Rigshospitalet in Copenhagen and the Spanish National Centre for Cardiovascular Research (CNIC) in Madrid, led by Henning Bundgaard and Borja Ibáñez. It enrolled adults in Denmark and Spain with no known atherosclerotic cardiovascular disease, in five pre-set age bands (18–29, 30–39, 40–49, 50–59 and 60–70) with balanced numbers of women and men. Mean age was 45, and 51.4% were women. Every participant had three-dimensional ultrasound of the carotid (neck) and femoral (leg) arteries plus a CT angiogram of the coronary arteries (CNIC; ESC). The results were presented at the European Society of Cardiology Congress in Munich on 29 August 2026 and published the same day in the New England Journal of Medicine.
Silent atherosclerosis was present in 57.1% of participants (95% confidence interval 56.3 to 58.0). In the youngest band, 18 to 29, it was present in 8.7% of men and 6.7% of women. Prevalence rose with age, with what the authors describe as a later, steeper midlife rise in women. By 60 to 70, about nine in ten had it.
Share with silent plaque, by age and sex
Bundgaard et al., NEJM 2026. The 18–29 figures and the overall figure are from the paper's abstract; the 30–39 and age-50 figures are as reported by Healio from the ESC Congress 2026 presentation; the 60–70 figure is the "9 in 10" in the CNIC and ESC press releases. Each age band held balanced numbers of men and women.
Two more findings matter for what follows. First, in the younger age bands plaque was most often peripheral, in the neck or leg arteries, and confined to a single territory; with age, plaque volume rose exponentially and disease in several arteries became common. Isolated coronary-artery disease, plaque in the heart arteries but nowhere else, was uncommon at every age (no more than 9.3% of men and 5.0% of women). Second, when the researchers ran SCORE2, the European risk calculator built on age, sex, smoking, blood pressure and cholesterol, it classified only a small minority of people with imaging-confirmed plaque as high risk, with the gap widest among the young (ESC). In other words, a score built to be cautious about false alarms missed most of the people who actually had the disease.
Bundgaard's summary at the congress was blunt: the current approach "relies on an estimation – not on knowledge of the presence of the actual disease."
What Plaque Does and Doesn't Tell You
REACT is a cross-sectional study: one imaging visit, no follow-up yet. It shows, with unusual precision, how early and how commonly atherosclerosis begins. It does not show that finding plaque in a 32-year-old and treating it prevents a heart attack at 62. That's the question the planned second phase, REACT-PROTECT, is meant to answer from 2027 if funded (CNIC). Isabel Gonçalves, discussing the results at the congress, made the point in one line: "Detecting silent atherosclerosis is only valuable if you can do something about it" (Healio).
Three other limits. The cohort is two Northern and Southern European countries, so the rates may not transfer exactly to the US. "Plaque" here includes small deposits picked up by sensitive imaging, not only the kind that blocks blood flow. And the paper is about imaging, not blood tests: it doesn't tell us that measuring apoB or Lp(a) would have flagged these people. What it does establish is that the standard way of guessing who has disease, a risk score built mainly on age and a few numbers, was wrong far more often than right in people under 50.
REACT also isn't the first study to find this. The PESA cohort in Madrid, run by some of the same investigators, reported in 2017 that atherosclerotic plaque or coronary calcium was present in about 50% of 1,779 middle-aged adults (40 to 54) who had none of the classical risk factors: non-smokers with untreated blood pressure, fasting glucose and cholesterol all below the conventional cut-offs. After age and male sex, the strongest predictor of plaque in that "healthy" group was LDL cholesterol, at levels currently considered normal (CNIC, on Fernández-Friera et al., JACC 2017). That's the thread that leads to the two tests.
ApoB: Counting the Particles, Not the Cargo
Evidence: Strong — large cohorts, genetics and guideline-endorsedPlaque forms when cholesterol-carrying particles get trapped in the artery wall. Every one of those particles, LDL, VLDL, their remnants and Lp(a), is wrapped in a single molecule of a protein called apolipoprotein B. A 2019 review in JAMA Cardiology put the consequence plainly: "Because there is a single molecule of either apoB48 or apoB100 per particle, plasma apoB equals the total number of" atherogenic particles, and trapping of apoB particles "initiates and drives the atherosclerotic process from beginning to end" (Sniderman et al., 2019).
A standard LDL cholesterol number measures how much cholesterol those particles carry, not how many there are. Usually the two track each other. But the lipid content of particles varies, so, in the review's words, "plasma triglyceride and cholesterol are not always accurate measures of the number of apoB particles." The authors estimate that the groups whose apoB disagrees with their cholesterol numbers range from about 20% to about 60% of the population, depending on how discordance is defined. Someone with many small, cholesterol-poor particles, a common pattern with high triglycerides, a big waist or early insulin resistance, can have an ordinary LDL and a high apoB. That person's lipid panel looks fine. Their artery wall is seeing a lot of traffic.
Does the particle count predict events better? The largest direct test is a 2022 JAMA Cardiology analysis of 389,529 UK Biobank participants not on lipid-lowering drugs, plus 40,430 trial patients with established disease. ApoB, non-HDL cholesterol and triglycerides were each associated with heart attack on their own; assessed together, only apoB remained associated. The authors concluded that risk "was best captured by the number of apoB-containing lipoproteins, independent from lipid content (cholesterol or TG) or type of lipoprotein" (Marston et al., 2022). Observational, as all of this is, but consistent with the genetics and the mechanism.
What the 2026 guideline says
The ACC/AHA dyslipidemia guideline published in March 2026, the same one our midlife heart-numbers guide uses, keeps LDL cholesterol as the primary target: under 100 mg/dL for borderline or intermediate risk, under 70 for high risk, under 55 for people who already have cardiovascular disease. ApoB is positioned as the refinement: "ApoB testing can be useful to improve risk assessment and guide therapy once LDL-C and non–HDL-C goals are met, particularly in those with elevated triglycerides (>200 mg/dL), diabetes, or low achieved LDL-C (<70 mg/dL)" (AHA, 2026). Two of the writing committee, Pamela Morris and Ann Marie Navar, describe the apoB goals as aligned with the LDL tiers: "less than 55, 70, or 90 mg/dL" depending on risk category (HCPLive, 2026).
So the honest framing is: US guidance now gives apoB a defined role, with numeric goals, but still as a second step rather than a universal first test. For a man in his forties with a "borderline" LDL, a bigger waist or triglycerides creeping up, it's the single most informative add-on to the lipid panel, and the one most likely to reveal the discordant pattern that a normal LDL hides.
Lp(a): The One You Only Need Once
Evidence: Strong for risk — genetic; drug trials still unresolvedLipoprotein(a) is an LDL-like particle with an extra protein, apolipoprotein(a), bolted on. Its level is "predominantly (>90%) determined by genetic variability at the LPA locus," according to the European Atherosclerosis Society's 2022 consensus statement, which also notes that "lifestyle interventions have minimal impact" (Kronenberg et al., European Heart Journal 2022). You inherit it, it's set early, and it stays put. Because it's so stable, the same consensus "recommends testing Lp(a) concentration at least once in adults." The 2026 ACC/AHA guideline agrees, as a Class I recommendation: Lp(a) "should be measured at least once to identify those individuals at higher risk of ASCVD," and since lifestyle barely moves it, repeat testing is generally not needed (AHA; ACC).
It's common. The National Lipid Association estimates that roughly 20% of the global population have elevated Lp(a), above 50 mg/dL, and the EAS puts that at about 1.4 billion people (NLA; EAS). Median levels are higher in people of African and South Asian ancestry than European or East Asian. The US guideline treats it as a risk-enhancing factor from 125 nmol/L (50 mg/dL), "which is associated with about a 1.4-fold increased ASCVD risk," and levels of 250 nmol/L (100 mg/dL) or more carry roughly double the estimated risk. The EAS statement links high Lp(a) not only to heart attack but to aortic valve stenosis.
ApoB and Lp(a): what each one adds
| ApoB | Lp(a) | |
|---|---|---|
| What it measures | The number of cholesterol-carrying particles that can enter the artery wall (LDL, VLDL, remnants, Lp(a)) — one apoB per particle | An inherited LDL-like particle; level set more than 90% by the LPA gene |
| Why the lipid panel misses it | LDL-C measures cargo, not particle count; 20–60% of people are "discordant" | Not part of a standard panel; has to be ordered separately |
| 2026 ACC/AHA position | "Can be useful" once LDL and non-HDL goals are met, especially with triglycerides >200, diabetes or LDL <70 goals <90, <70 or <55 mg/dL by risk tier | Measure at least once in adulthood risk-enhancing from 125 nmol/L (50 mg/dL); ~2× risk from 250 nmol/L |
| How often | With each lipid panel if you're tracking it; it responds to diet, weight and drugs | Once is usually enough stable for life; repeat not generally needed |
| Fasting? | Labcorp asks for 12–14 hours | No special preparation |
| Direct-to-consumer list price US, October 2026 | $69 (Labcorp OnDemand) | $49 (Labcorp OnDemand) |
| What moves it | The same drugs, diet and weight changes that lower LDL | Lifestyle: minimal. Statins: no meaningful change. PCSK9 inhibitors: about 25–30% lower. Dedicated drugs: in trials |
Guideline wording from the AHA's summary of the 2026 ACC/AHA dyslipidemia guideline and the EAS 2022 Lp(a) consensus; particle facts from Sniderman et al. 2019; prices from Labcorp OnDemand product pages at the time of writing (Labcorp showed the apoB test discounted to $51.75). Prices and availability change; check before ordering.
If your Lp(a) is high
This is where honesty matters, because the obvious question, "can I lower it?", has an unsatisfying answer right now. Statins don't lower Lp(a) meaningfully. PCSK9 inhibitors reduce it by about 25–30% as a side effect of their LDL lowering (NLA). The drugs designed specifically to switch Lp(a) off are in late-stage trials, and the first to report did not go the way many hoped. On 4 September 2026 Novartis announced that pelacarsen, an antisense drug, lowered Lp(a) in the 8,323-patient Lp(a)HORIZON trial but did not reduce major cardiovascular events against placebo in people who already had cardiovascular disease (NLA; TCTMD). Four other outcome trials continue: OCEAN(a)-Outcomes and OCEAN(a)-PreEvent (olpasiran, Amgen), ACCLAIM-Lp(a) (lepodisiran, Lilly) and MOVE-Lp(a) (muvalaplin, Lilly). Until they read out, nobody can say whether lowering Lp(a) with a drug prevents events.
What a high result changes today is everything around it. The NLA's response to the pelacarsen result was that "clinicians and patients should continue to measure Lp(a)" and manage risk by optimizing lifestyle and reaching LDL and non-HDL cholesterol goals. The EAS says the same: "early intensive risk factor management is recommended, targeted according to global cardiovascular risk and Lp(a) level." In practice that means a high Lp(a) can move someone from "watch and wait" on a borderline LDL to treating it, tightens the blood pressure and glucose targets, and, per the 2026 guideline, should prompt testing of first-degree relatives, since they have a good chance of carrying it too (HCPLive). Knowing is useful even before there's a pill for it.
How to Get the Tests, and When a Scan Adds Something
Ask your doctor first. Both tests are ordinary blood draws that any lab runs; the only reason most people have never had them is that nobody added them to the order. Ask for apoB and Lp(a) to be added to your next lipid panel, and for your PREVENT 10- and 30-year risk estimate, which the 2026 guideline uses for adults aged 30 to 79. Insurance coverage varies, but at list prices these are among the cheapest tests in medicine.
Direct-to-consumer, in most states. If your doctor won't order them, or you'd rather see the numbers first, the two national lab chains sell them online with a physician order built into the purchase. At the time of writing Labcorp OnDemand listed apoB at $69 (on sale at $51.75) and Lp(a) at $49, with results in a few days from a draw at a Labcorp site (Labcorp apoB; Labcorp Lp(a)). Quest Health listed an Advanced Heart Health panel at $215 plus a $6 physician fee that bundles a standard lipid panel with apoB, Lp(a), hs-CRP and particle fractionation (Quest Health). Availability depends on state laboratory law: Quest's consumer site says its tests "are not currently available in Arizona, Hawaii, and Puerto Rico" (Quest Health FAQ), the physician-network terms on Labcorp's site say the services "may not be available in certain U.S. states," and at least one third-party testing service says state laws impose "specific restrictions" on its orders from New York, New Jersey, Rhode Island, Massachusetts and Pennsylvania (Life Extension FAQ). If you live in one of those, check whether the service you choose will accept your order; the doctor route always works.
When a calcium scan adds information
A coronary artery calcium (CAC) scan is a quick, low-dose CT that counts calcified plaque in the heart arteries. It's not a blood test and it doesn't replace apoB or Lp(a); it answers a different question, whether disease is already there. The 2026 guideline recommends "selective use" of it "for men over the age of 40 and women over the age of 45 with borderline or intermediate 10-year risk," and says any calcium at all supports an LDL goal under 100 mg/dL, with lower targets for higher scores (ACC). That's the sweet spot: a man in his late forties or fifties whose risk estimate sits in the grey zone, where a zero argues for holding off on medication and a positive score settles the argument the other way. GoodRx puts the cash price at $100 to $400, typically $100 to $150 out of pocket, and notes that most insurance plans, including original Medicare, don't cover the test (GoodRx, 2025).
REACT adds a caution for younger men. In its under-40 bands, plaque was most often in the carotid or femoral arteries and confined to one territory; isolated coronary disease was rare. A heart calcium scan looks only at the coronaries, and only at calcified plaque, so a zero at 35 says less than it does at 55. For that group, the blood tests are the better early signal, and if imaging is wanted, a carotid ultrasound is the territory where REACT most often found it.
The practical version. If you're a man over 35 and have never had apoB or Lp(a) measured, get both with your next lipid panel. Lp(a) you'll never need again unless it's high. ApoB becomes the number you track, alongside waist, blood pressure and glucose, because it's the one that responds to what you do. Take the results to your doctor and ask where your apoB sits against the 2026 goals for your risk tier, and whether your 10-year risk is in the range where a calcium scan would change the decision. None of this is medical advice; it's the list of questions that the REACT findings make worth asking.
Frequently Asked Questions
Feeling fine is not a test result.
REACT looked inside the arteries of 16,808 people who had no reason to think anything was wrong, and found plaque in more than half, including about one in thirteen under thirty and half of all men by fifty. The risk score most of them would have been given at a check-up called almost none of them high risk.
Imaging everyone isn't the answer yet; nobody has shown that it prevents heart attacks. But two cheap blood tests measure the particles that build the plaque, and one of them only needs doing once. Ask for apoB and Lp(a) with your next panel, and take the numbers to your doctor.
Sources
- Bundgaard H, García-Lunar I, Kofoed KF, Hasselbalch R, et al., for the REACT Investigators. Prevalence of Silent Atherosclerosis across Adult Life. New England Journal of Medicine, published online 29 August 2026 (doi:10.1056/NEJMoa2609059). Abstract checked via Europe PMC.
- Centro Nacional de Investigaciones Cardiovasculares (CNIC). NEJM: REACT reveals that silent atherosclerosis already affects 1 in 13 young adults aged 18 to 29 and progresses rapidly from the menopause. Press release, 29 August 2026.
- European Society of Cardiology. Early imaging of atherosclerosis identifies silent disease not captured by conventional risk assessment. Press release, ESC Congress 2026, 29 August 2026.
- Healio. More than half of healthy adults have silent atherosclerosis. 30 August 2026.
- CNIC. 'JACC': LDL cholesterol is the main modifiable predictor of atherosclerosis in people with no classical risk factors (on Fernández-Friera L, et al. Normal LDL-Cholesterol Levels Are Associated With Subclinical Atherosclerosis in the Absence of Risk Factors. JACC 2017;70:2979–2991).
- Sniderman AD, Thanassoulis G, Glavinovic T, et al. Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review. JAMA Cardiology 2019;4:1287–1295.
- Marston NA, Giugliano RP, Melloni GEM, et al. Association of Apolipoprotein B–Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis. JAMA Cardiology 2022 (UK Biobank publication summary).
- American Heart Association. 2026 Guideline on the Management of Dyslipidemia: Top Things to Know.
- American College of Cardiology. ACC, AHA Release New Clinical Guideline for Managing Dyslipidemia. 13 March 2026 (Blumenthal RS, Morris PB, et al. JACC, doi:10.1016/j.jacc.2025.11.016).
- Morris PB, Navar AM. Expert Insights: Lp(a) and ApoB in the 2026 Dyslipidemia Guidelines. HCPLive, 23 March 2026.
- Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. European Heart Journal 2022;43:3925–3946.
- Shemisa K, Koschinsky M. The ABCs of Lipoprotein(a). National Lipid Association, Lipid Spin, May 2023.
- National Lipid Association. Top Line Results from the Phase 3 Lp(a)HORIZON Trial. September 2026.
- TCTMD. Lp(a)HORIZON: Top-line Results Dash Hopes for Pelacarsen. 8 September 2026.
- Labcorp OnDemand. Apolipoprotein B (ApoB) Test and Lipoprotein(a) Test; PWNHealth agreements. Accessed October 2026.
- Quest Health. Advanced Heart Health Test Panel (with ApoB); Are there any states or territories where I cannot purchase lab testing? Accessed October 2026.
- Life Extension. Blood Testing Services: Frequently Asked Questions. Accessed October 2026.
- GoodRx. Coronary Artery Calcium Scan Cost and Savings Tips. 28 August 2025.